An overview on severe acute respiratory syndrome (SARS)

Monaldi Archives for Chest Disease - Pulmonary Series

Volumn 63, Issue 3, 2005, Pages 149-157

  Hui, David S C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Clinical features; Epidemiology; Pharmacotherapy; SARS

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; AMINOTRANSFERASE; BAICALIN; BETA INTERFERON; BETA1 INTERFERON; CONSENSUS INTERFERON; CORTICOSTEROID DERIVATIVE; DNA VACCINE; GAMMA INTERFERON; GLYCYRRHIZIC ACID; HUMAN MONOCLONAL ANTIBODY; HYDROCORTISONE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; METHYLPREDNISOLONE; NELFINAVIR; NITRIC OXIDE; OXYGEN; PEGINTERFERON; PENTAGLOBULIN; RECOMBINANT BETA INTERFERON; RECOMBINANT PROTEIN; RIBAVIRIN; RITONAVIR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA VACCINE; VIRUS VACCINE;

ADULT RESPIRATORY DISTRESS SYNDROME; AMINOTRANSFERASE BLOOD LEVEL; ANTIGENICITY; ANTIVIRAL ACTIVITY; ARTIFICIAL VENTILATION; BRADYCARDIA; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONVALESCENCE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG PULSE THERAPY; DRUG RECEPTOR BINDING; EPIDEMIC; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INFECTION RISK; MORTALITY; NONHUMAN; OXYGEN SUPPLY; PASSIVE IMMUNIZATION; PEDIATRICS; PLASMA TRANSFUSION; POLYNEUROPATHY; QUANTITATIVE ANALYSIS; RESPIRATORY FAILURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; RNA EXTRACTION; RNA INTERFERENCE; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SIDE EFFECT; SURVIVAL RATE; SYMPTOMATOLOGY; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRUS LOAD; VIRUS REPLICATION;

EID: 28244444516     PISSN: 11220643     EISSN: 2465101X     Source Type: Journal    
DOI: 10.4081/monaldi.2005.632     Document Type: Review

References (120)

1. Lee N, Hui DS, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348: 1986-1994.
2. Hsu LY, Lee CC, Green JA, et al. Severe acute respiratory syndrome in Singapore: Clinical features of index patient and initial contacts. Emerg Infect Dis 2003; 9: 713-717.
3. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003; 289: 2801-2809.
4. Twu SJ, Chen TJ, Chen CJ, et al. Control measures for severe acute respiratory syndrome (SARS) in Taiwan. Emerg Infect Dis 2003; 9: 718-720.
5. WHO. Summary of probable SARS cases with onset of illness from 1 November to 31 July 2003. Available from: http://www.who.int/csr/sars/country/table2003_09_23/en.
6. Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361: 1319-1325.
7. Kuiken T, Fouchier RA, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003; 362: 263-270.
8. Drosten C, Gunther S, Preiser W, et al. Identification of a novel Coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1967-1976.
9. Ksiazek TG, Erdman D, Goldsmith CS, et al. A Novel Coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1953-1966.
10. Fouchier RA, Kuiken T, Schutten M, et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 2003; 423: 240.
11. Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300: 1394-1399.
12. Marra MA, Jones SJ, Astell CR, et al. The genome sequence of the SARS-associated coronavirus. Science 2003; 300: 1399-1404.
13. Ruan YJ, Wei CL, Ee LA, et al. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 2003; 361: 1779-1785.
14. Zhao Z, Zhang F, Xu M, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003; 52: 715-720.
15. Xu RH, He JF, Evans MR, et al. Epidemiologic clues to SARS origin in China. Emerg Infect Dis 2004; 10: 1030-1037.
16. Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome in Guangdong, People's Republic of China, in Feb 2003. Lancet 2003; 362: 1353-1358.
17. Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003; 302: 276-278.
18. The Chinese SARS Molecular Epidemiology Consortium. Molecular Evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 2004; 303: 1666-1669
19. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348: 1977-1985.
20. Peiris JS, Yuen KY, Osterhaus AD, et al.: The severe acute respiratory syndrome. N Engl J Med 2003; 349: 2431-2441.
21. Wong RS, Hui DS. Index patient and SARS outbreak in Hong Kong. Emerg Infect Dis 2004; 10: 339-341.
22. Loon SC, Teoh SC, Oon LL, et al. The severe acute respiratory syndrome coronavirus in tears. Br J Ophthalmol 2004; 88: 861-863.
23. Yu IT, Li Y, Wong TW, et al. Evidence of airborne transmission of the severe acute respiratory syndrome virus. N Engl J Med 2004; 350: 1731-1739.
24. Ng SK. Possible role of an animal vector in the SARS outbreak at Amoy Gardens. Lancet 2003; 362: 570-572.
25. Lee SH. The SARS epidemic in Hong Kong. J Epidemiol Community Health 2003; 57: 652-654.
26. Booth TF, Kournikakis B, Bastien N, et al. Detection of airborne Severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J Infect Dis 2005; 191: 1472-1477.
27. Yu IT, Wong TW, Chiu YL, et al. Temporal-spatial analysis of Severe acute respiratory syndrome among hospital inpatients. Clin Infect Dis 2005; 40: 1237-1243.
28. Leung GM, Hedley AJ, Ho LM, et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann Intern Med 2004; 141: 662-673.
29. Hui DS, Wong PC, Wang C. Severe acute respiratory syndrome: Clinical features and diagnosis. Respirol 2003; 8: S20-S24.
30. Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361: 1767-1772.
31. Leung WK, To KF, Chan PK, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterol 2003; 125: 1011-1017.
32. Chan HL, Kwan AC, To KF, et al. Clinical significance of hepatic derangement in Severe acute respiratory syndrome. World J Gastroenterol 2005; 11: 2148-2153.
33. Hung EC, Chim SS, Chan PK, et al. Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome. Clin Chem 2003; 49: 2108-2109.
34. Lau KK, Yu WC, Chu CM, et al. Possible central nervous system infection by SARS coronavirus. Emerg Infect Dis 2004; 10: 342-344.
35. Wong KC, Leung KS, Hui M. Severe acute respiratory syndrome (SARS) in a geriatric patient with a hip fracture. A case report. J Bone Joint Surg 2003; 85A: 1339-1342.
36. Lee AK, Oh HM, Hui KP, et al. Atypical SARS in a geriatric patient. Emerg Infect Dis 2004; 10: 261-264.
37. Fisher DA, Lim TK, Lim YT, et al. Atypical presentations of SARS. Lancet 2003; 361: 1740.
38. Hon KL, Leung CW, Cheng WT, et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet 2003; 561: 1701-1703.
39. Sit SC, Yau EKC, Lam YY, et al. A young infant with severe acute respiratory syndrome. Pediatrics 2003; 112: e257-260.
40. Bitnun A, Allen U, Heurter H, et al. Children hospitalized with severe acute respiratory syndrome-related illness in Toronto. Pediatrics 2003; 112: e261-268.
41. Chiu WK, Cheung PC, Ng KL et al. Severe acute respiratory syndrome in children: Experience in a regional hospital in Hong Kong. Pediatr Crit Care Med 2003; 4: 279-283.
42. Hui DS, Wong KT, Antonio GE, et al. Severe Acute Respiratory Syndrome (SARS): Correlation of Clinical Outcome and Radiological Features. Radiology 2004; 233: 579-585.
43. Hui DS, Sung JJ. Severe acute respiratory syndrome. Chest 2003; 124: 12-15.
44. Wong GW, Hui DS. Severe acute respiratory syndrome: Epidemiology, Diagnosis and Treatment. Thorax 2003; 58: 558-560.
45. Wong RS, Wu A, To KF et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. Brit Med J 2003; 326: 1358-1362.
46. Chen X, Zhou B, Li M, et al. Serology of severe acute respiratory syndrome: implications for surveillance and outcome. J Infect Dis 2004; 189: 1158-1163.
47. Muller MP, Tomlinson G, Marrie TJ, et al. Can routine laboratory tests discriminate between Severe acute respiratory syndrome and other causes of community acquired pneumonia? Clin Infect Dis 2005; 40: 1079-1086.
48. Wong KT, Antonio GE, Hui DS, et al. Severe Acute Respiratory Syndrome: Radiographic appearances and pattern of progression in 138 Patients. Radiology 2003; 228: 401-406.
49. Gomersall CD, Joynt GM, Lam P, et al. Short-term outcome of critically ill patients with severe acute respiratory syndrome. Intensive Care Med 2004; 30: 381-387.
50. Wong KT, Antonio GE, Hui DS, et al. Thin section CT of Severe Acute Respiratory Syndrome: Evaluation of 73 patients exposed to or with the disease. Radiology 2003; 228: 395-400.
51. Poon LL, Chan KH, Wong OK, et al. Early diagnosis of SARS coronavirus infection by real time RT-PCR. J Clin Virol 2003; 28: 233-238.
52. Ng EK, Hui DS, Chan KC, et al. Quantitative analysis and prognostic implication of SARS coronavirus in the plasma and serum of patients with severe acute respiratory syndrome. Clin Chem 2003; 49: 1976-1980.
53. Ng EK, Ng PC, Hon KL et al. Serial analysis of the plasma concentration of SARS coronavirus RNA in pediatric patients with severe acute respiratory syndrome. Clin Chem 2003; 49: 2085-2088.
54. Grant PR, Garson JA, Teddar RS et al. Detection of SARS coronavirus in plasma by real-time RT-PCR. N Engl J Med 2003; 349: 2468-2469.
55. Cinatl J, Morgenstern B, Bauer G et al. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003; 361: 2045-2046.
56. Tan EL, Ooi EE, Lin CY et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis 2004; 10: 581-586.
57. Stroher U, DiCaro A, Li Y et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α. J Infect Dis 2004; 189: 1164-1167.
58. Sung JJ, Wu A, Joynt GM, et al. Severe Acute Respiratory Syndrome: Report of treatment and outcome after a major outbreak. Thorax 2004; 59: 414-420.
59. Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3Clpro) structure: basis for design of anti-SARS drugs. Science 2003; 300: 1763-1767.
60. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59: 252-256.
61. Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicenter retrospective matched cohort study. Hong Kong Med J 2003; 9: 399-406.
62. Hurst M, Faulds D. Lopinavir. Drugs 2000; 60: 1371-1381.
63. Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Com 2004; 318: 719-725.
64. Cinatl J, Morgenstern B, Bauer G, et al. Treatment of SARS with human interferons. Lancet 2003; 362: 293-294.
65. Hensley LE, Fritz EA, Jahrling PB, et al. Interferon-β 1a and SARS coronavirus replication. Emerg Infect Dis 2004; 10: 317-319.
66. Sainz B Jr, Mossel EC, Peters CJ, et al. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology 2004; 329: 11-17.
67. Morgenstern B, Michaelis M, Baer PC, et al. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun 2005; 326: 905-908.
68. Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 2005; 39: 69-75.
69. Haagmans BL, Kuiken T, Martina BE, et al. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nature Med 2004; 10: 290-293.
70. Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon Alfacon-1 plus corticosteroids in severe acute respiratory syndrome. A Preliminary Study. JAMA 2003; 290: 3222-3228.
71. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426: 450-454.
72. Sui, J, Li W, Murakami A, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Nat'l Acad Sci 2004; 101: 2536-2541.
73. ter Meulen J, Bakker AB, van den Brink EN, et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 2004; 363: 2139-2141.
74. Gao W, Tamin A, Soloff A, et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 2003; 362: 1895-1896.
75. Zhao P, Ke JS, Qin ZL et al. DNA vaccine of SARS-CoV S gene induces antibody response in mice. Acta Biochim et Biophysica Sinica 2004; 36: 37-41.
76. Yang ZY, Kong WP, Huang Y, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004; 428: 561-564.
77. Ho TY, Wu SL, Cheng SE et al. Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein. Biochem Biophys Res Commun 2004; 313: 938-947.
78. Bisht H, Roberts A, Vogel L, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Nat'l Acad Sci 2004; 101: 6641-6646.
79. Bukreyev A, Lamirande EW, Buchholz UJ, et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 2004; 363: 2122-2127.
80. Choy WY, Lin SG, Chan PK, et al. Synthetic peptide studies on the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein: perspective for SARS vaccine development. Clin Chem 2004; 50: 1036-1042.
81. Bosch BJ, Martina BE, van der Zee R, et al. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Nat'l Acad Sci 2004; 101: 8455-8460.
82. Subbarao K, McAuliffe J, Vogel L, et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 2004; 78: 3572-3577.
83. Traggiai E, Becker S, Subbarao K, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 2004; 10: 871-875.
84. Ho JC, Ooi GC, Mok TY et al. High dose pulse versus non-pulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med 2003; 168: 1449-1456.
85. Wong CK, Lam CWK, Wu AK et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004; 136: 95-103.
86. Jiang Y, Xu J, Zhou C, et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med 2005; 171: 850-857.
87. Tsang OT, Chau TN, Choi KW, et al. Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg Infect Dis 2003; 9: 1381-1387.
88. Wang H, Ding Y, Li X, et al. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 2003; 349: 507-508.
89. Hong N, Du XK. Avascular necrosis of bone in severe acute respiratory syndrome. Clin Radiol 2004; 59: 602-608.
90. Griffith JF, Antonio GE, Kumta SM, et al. Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology 2005; 235: 168-175.
91. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 2004; 31: 304-309.
92. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24: 44-46.
93. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. J Clin Microbiol 2004; 10: 676-678.
94. Liu BY, Hu JQ, Xie YM, et al. Effects of integrative Chinese and Western Medicine on arterial oxygen saturation in patients with Sever acute respiratory syndrome. CJIM 2004; 10: 117-122.
95. Zheng BJ, Guan Y, Tang Q, et al. Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus. Antivir Ther 2004; 9: 365-374.
96. Wu CJ, Huang HW, Liu CY, et al. Inhibition of SARS-CoV replication by siRNA. Antivir Res 2005; 65: 45-48.
97. Li BJ, Tang Q, Cheng D, et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in rhesus macaque. Nat Med 2005; 11: 944-951.
98. Ballow M. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol 1997; 100: 151-157.
99. Lew TW, Kwek TK, Tai D, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA 2003; 290: 374-380.
100. Chong PY, Chui P, Ling AE, et al. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Arch Pathol Lab Med 2004; 128: 195-204.
101. Umapathi T, Kor AC, Venketasubramanian N, et al. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). J Neurol 2004; 251: 1227-1231.
102. Ho JC, Wu AY, Lam B, et al. Pentaglobin in steroid-resistant severe acute respiratory syndrome. Int J Tuberc Lung Dis 2004; 8: 1173-1179.
103. Ng KH, Wu AK, Cheng VC, et al. Pulmonary artery thrombosis in a patient with Severe acute respiratory syndrome (SARS). Postgrad Med J 2005; 81: e3.
104. Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurol 2003; 60: 1763-1767.
105. Chen L, Liu P, Gao H, et al. Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing. Clin Infect Dis 2004; 39: 1531-1535.
106. Akerstrom S, Mousavi-Jazi M, Klingstrom J, et al. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol 2005; 79: 1966-1969.
107. Fowler RA, Guest CB, Lapinsky SE, et al. Transmission of severe acute respiratory syndrome during intubation and mechanical ventilation. Am J Respir Crit Care Med 2004; 169: 1198-1202.
108. Cheung TM, Yam LY, So LK, et al. Effectiveness of noninvasive positive pressure ventilation in the treatment of acute respiratory failure in severe acute respiratory syndrome. Chest 2004; 126: 845-850.
109. Hui DS, Sung JJ. Editorial: Treatment of Severe acute respiratory syndrome. Chest 2004; 126: 670-674.
110. Tsui PT, Kwok ML, Yuen H, et al. Severe acute respiratory syndrome: Clinical outcome and prognostic correlates. Emerg Infect Dis 2003; 9: 1064-1069.
111. Chan JW, Ng CK, Chan YH, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with Severe acute respiratory syndrome (SARS). Thorax 2003; 58: 686-689.
112. Chu CM, Poon LL, Cheng VC, et al. Initial viral load and the outcomes of SARS. CMAJ 2004; 171: 1349-1352.
113. Hui DS, Joynt GM, Wong KT, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax 2005; 60: 401-409.
114. Hui DS, Wong KT, Ko FW, et al. The one-year impact of Severe Acute Respiratory Syndrome (SARS) on pulmonary function, exercise capacity and quality of life in a cohort of survivors. Chest 2005, in press.
115. Tsai LK, Hsieh ST, Chao CC, et al. Neuromuscular disorders in severe acute respiratory syndrome. Arch Neurol 2004; 61: 1669-1673.
116. Chua SE, Cheung V, McAlonan GM, et al. Stress and psychological impact on SARS patients during the outbreak. Can J Psychiatry 2004; 49: 385-390.
117. Cheng SK, Wong CW, Tsang J, et al. Psychological distress and negative appraisals in survivors of severe acute respiratory syndrome (SARS). Psychol Med 2004; 34: 1187-1195.
118. Lee DT, Wing YK, Leung HC, et al. Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study. Clin Infect Dis 2004; 39: 1247-1249.
119. Yu WC, Hui DS, Chan M. Editorial: Antivirals and corticosteroids in the treatment of SARS. Thorax 2004; 59: 643-645.
120. Tsang KW, Ooi GC, Ho PL. Diagnosis and pharmacotherapy of severe acute respiratory syndrome: what have we learnt? Eur Respir J 2005; 24: 1025-1032.